Erwin R. Boghaert

8.0k citations

58 papers · 2.5k indexed · h-index 26

Molecular Biology top 10%
Oncology top 2%
Radiology, Nuclear Medicine and Imaging top 5%
Hematology top 2%
Pathology and Forensic Medicine top 5%

Co-authors: Nitin K. Damle John F. DiJoseph Maureen Dougher Douglas Armellino Philip R. Hamann Arthur Kunz Latha Sridharan Justin Moran
Topics: Cancer Cells and Metastasis (11 papers)Monoclonal and Polyclonal Antibodies Research (11 papers)3D Printing in Biomedical Research (7 papers)
Cited by: Oncology Hematology Genetics
Journals: Journal of Clinical Oncology Blood Molecular and Cellular Biology
Partner nations: United States Portugal United Kingdom

In The Last Decade

Erwin R. Boghaert

57 papers receiving 2.4k citations

Peers

Countries citing papers authored by Erwin R. Boghaert

Since Specialization

Citations

This map shows the geographic impact of Erwin R. Boghaert's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Erwin R. Boghaert with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Erwin R. Boghaert more than expected).

Fields of papers citing papers by Erwin R. Boghaert

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Erwin R. Boghaert. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Erwin R. Boghaert. The network helps show where Erwin R. Boghaert may publish in the future.

Co-authorship network of co-authors of Erwin R. Boghaert

This figure shows the co-authorship network connecting the top 25 collaborators of Erwin R. Boghaert. A scholar is included among the top collaborators of Erwin R. Boghaert based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Erwin R. Boghaert. Erwin R. Boghaert is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Exploring Metabolic Signatures of Ex Vivo Tumor Tissue Cultures for Prediction of Chemosensitivity in Ovarian Cancer 2022 ·Cancers ·Rita Mendes,Gonçalo Graça,Fernanda Silva,Ana C. L. Guerreiro,Patrícia Gomes‐Alves,Jacinta Serpa,Erwin R. Boghaert,Paula M. Alves,Ana Félix,Catarina Brito,(unknown)	7
2	Patient-Derived Explants of Colorectal Cancer: Histopathological and Molecular Analysis of Long-Term Cultures 2021 ·Cancers ·(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),Cristina Albuquerque,Ricardo Roberto de Souza Fonseca,Vítor Espirito Santo,Erwin R. Boghaert,Isadora Rosa,Catarina Brito	11
3	Application of LDH assay for therapeutic efficacy evaluation of ex vivo tumor models 2021 ·Scientific Reports ·(unknown),Rita Mendes,Fernanda Silva,(unknown),(unknown),(unknown),Julie J. Purkal,(unknown),Ana Félix,Erwin R. Boghaert,Catarina Brito	38
4	Synergistic therapeutic benefit by combining the antibody drug conjugate, depatux-m with temozolomide in pre-clinical models of glioblastoma with overexpression of EGFR 2021 ·Journal of Neuro-Oncology ·Kedar S. Vaidya,Michael J. Mitten,(unknown),Anatol Oleksijew,Cory Alvey,Hugh D. Falls,(unknown),Joann P. Palma,Peter Ansell,Andrew C. Phillips,Edward B. Reilly,Mark G. Anderson,Erwin R. Boghaert	9
5	Targeting Multiple EGFR-expressing Tumors with a Highly Potent Tumor-selective Antibody–Drug Conjugate 2020 ·Molecular Cancer Therapeutics ·Mark G. Anderson,Hugh D. Falls,Michael J. Mitten,Anatol Oleksijew,Kedar S. Vaidya,Erwin R. Boghaert,Wenqing Gao,Joann P. Palma,Diana Cao,(unknown),Thomas John,Hui Gan,Andrew M. Scott,Edward B. Reilly	30
6	Patient-derived ovarian cancer explants: preserved viability and histopathological features in long-term agitation-based cultures 2020 ·Scientific Reports ·(unknown),Fernanda Silva,Rita Mendes,(unknown),(unknown),Vítor Espirito Santo,Erwin R. Boghaert,Ana Félix,Catarina Brito	24
7	5-Azacitidine Induces NOXA to Prime AML Cells for Venetoclax-Mediated Apoptosis 2020 ·Clinical Cancer Research ·Sha Jin,Dan Cojocari,Julie J. Purkal,Relja Popovic,Nari Talaty,Xiao Yu,Larry R. Solomon,Erwin R. Boghaert,Joel Johansson,Darren C. Phillips	126
8	FLT3-ITD Activation Mediates Resistance to the BCL-2 Selective Antagonist, Venetoclax, in FLT3-ITD Mutant AML Models 2017 ·Blood ·Raghuveer Singh Mali,Elisabeth A. Lasater,Kelly Doyle,(unknown),Erwin R. Boghaert,Andrew J. Souers,Joel Johansson,Deepak Sampath	17
9	The Volume of Three-Dimensional Cultures of Cancer Cells In Vitro Influences Transcriptional Profile Differences and Similarities with Monolayer Cultures and Xenografted Tumors 2017 ·Neoplasia ·Erwin R. Boghaert,Xin Lü,Paul Hessler,Thomas McGonigal,Anatol Oleksijew,Michael J. Mitten,(unknown),Jonathan A. Hickson,Vítor Espirito Santo,Catarina Brito,Tamar Uziel,Kedar S. Vaidya	25
10	ABBV-399, a c-Met Antibody–Drug Conjugate that Targets Both MET –Amplified and c-Met–Overexpressing Tumors, Irrespective of MET Pathway Dependence 2016 ·Clinical Cancer Research ·Jieyi Wang,Mark G. Anderson,Anatol Oleksijew,Kedar S. Vaidya,Erwin R. Boghaert,Lora A. Tucker,Qian Zhang,Edward K. Han,Joann P. Palma,Louie Naumovski,Edward B. Reilly	104
11	ABT-414, an Antibody–Drug Conjugate Targeting a Tumor-Selective EGFR Epitope 2016 ·Molecular Cancer Therapeutics ·Andrew C. Phillips,Erwin R. Boghaert,Kedar S. Vaidya,Michael J. Mitten,Suzanne M. Norvell,Hugh D. Falls,Peter J. DeVries,Dong Cheng,Jonathan A. Meulbroek,Fritz G. Buchanan,Laura M. McKay,Neal Goodwin,Edward B. Reilly	136
12	Expression Profile of BCL-2, BCL-XL, and MCL-1 Predicts Pharmacological Response to the BCL-2 Selective Antagonist Venetoclax in Multiple Myeloma Models 2016 ·Molecular Cancer Therapeutics ·Elizabeth A. Punnoose,Joel Johansson,Franklin Peale,Erwin R. Boghaert,Lisa D. Belmont,Nguyen Tan,A. Young,Michael J. Mitten,Ellen Ingalla,Walter C. Darbonne,Anatol Oleksijew,Paul Tapang,Yue Peng,Jason Oeh,Leslie Lee,Sophie Maïga,Wayne J. Fairbrother,Martine Amiot,Andrew J. Souers,Deepak Sampath	223
13	Antitumor Efficacy of a Combination of CMC-544 (Inotuzumab Ozogamicin), a CD22-Targeted Cytotoxic Immunoconjugate of Calicheamicin, and Rituximab against Non-Hodgkin's B-Cell Lymphoma 2006 ·Clinical Cancer Research ·John F. DiJoseph,Maureen Dougher,(unknown),Douglas Armellino,Erwin R. Boghaert,Philip R. Hamann,Justin Moran,Nitin K. Damle	103
14	CD20-specific antibody-targeted chemotherapy of non-Hodgkin’s B-cell lymphoma using calicheamicin-conjugated rituximab 2006 ·Cancer Immunology Immunotherapy ·John F. DiJoseph,Maureen Dougher,Douglas Armellino,(unknown),Arthur Kunz,Erwin R. Boghaert,Philip R. Hamann,Nitin K. Damle	42
15	Antibody-targeted chemotherapy of B-cell lymphoma using calicheamicin conjugated to murine or humanized antibody against CD22 2004 ·Cancer Immunology Immunotherapy ·John F. DiJoseph,Andrew G. Popplewell,Simon Tickle,Heather M. Ladyman,Alastair D. G. Lawson,Arthur Kunz,Kiran Khandke,Douglas Armellino,Erwin R. Boghaert,Philip R. Hamann,K Zinkewich-Péotti,Sue Stephens,Neil Weir,Nitin K. Damle	55
16	Expression and Function of the Leucine Zipper Protein Par-4 in Apoptosis 1997 ·Molecular and Cellular Biology ·Stephen F. Sells,Seong‐Su Han,Sumathi Muthukkumar,(unknown),Ricky W. Johnstone,Erwin R. Boghaert,David Gillis,Guohui Liu,Prakash Nair,(unknown),(unknown),Mark P. Mattson,Vikas P. Sukhatme,Stephen G. Zimmer,David P. Wood,J. William McRoberts,Yang Shi,Vivek M. Rangnekar	159
17	Quantitative and qualitative differences in growth, invasion and lung colonization of an anaplastic and a papillary human thyroid cancer cell linein vitro andin vivo 1996 ·Clinical & Experimental Metastasis ·Erwin R. Boghaert,Kenneth B. Ain,(unknown),(unknown),Carol L. Fowler,Stephen G. Zimmer	7
18	Metastasis of C1300 and TBJ murine neuroblastomas correlates with expression of matrix metalloproteinases 1995 ·Cancer Letters ·Carol L. Fowler,(unknown),Erwin R. Boghaert,(unknown),Stephen G. Zimmer	7
19	Increasing N-CAM-mediated cell-cell adhesion does not reduce invasion of RSV-transformed WC5 rat cerebellar cells 1993 ·Clinical & Experimental Metastasis ·Susann M. Brady‐Kalnay,Erwin R. Boghaert,S G Zimmer,Robert Brackenbury	4
20	The influence of the presence of adenovirus 5 E1a and E1b sequences on the pathology of rat embryonic fibroblasts transfected with activated c-Ha-ras and v-ras 1991 ·Clinical & Experimental Metastasis ·Erwin R. Boghaert,(unknown),S G Zimmer	3

About Erwin R. Boghaert

Erwin R. Boghaert is a scholar working on Oncology, Hematology and Genetics, having authored 58 papers that have together received 2.5k indexed citations. Recurring topics across this work include Cancer Cells and Metastasis (11 papers), Monoclonal and Polyclonal Antibodies Research (11 papers) and 3D Printing in Biomedical Research (7 papers). The work is most often cited by research in Oncology (1.0k citations), Hematology (370 citations) and Genetics (302 citations). Erwin R. Boghaert has collaborated with scholars based in United States, Portugal and United Kingdom. Frequent co-authors include Nitin K. Damle, John F. DiJoseph, Maureen Dougher, Douglas Armellino, Philip R. Hamann, Arthur Kunz, Latha Sridharan, Justin Moran, Kiran Khandke and Catarina Brito. Their work appears in journals such as Journal of Clinical Oncology, Blood and Molecular and Cellular Biology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact